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Amplification of mixed lineage leukemia gene 
perturbs hematopoiesis and cooperates with partial 
tandem duplication to induce acute myeloid
leukemia
Genetic alternation of the mixed lineage leukemia
(MLL) gene can be found in up to 10% of acute myeloid
leukemia (AML).1,2 Similar to MLL fusions and MLL par-
tial tandem duplication (PTD), MLL amplification 
(MLL(n)) is reported in approximately 1% AML and
myelodysplastic syndrome (MDS) associates with
adverse treatment outcomes.3,4 In spite of the success in
modeling AML induced by MLL fusions,1 there has been
no in vivo disease model for MLL(n) leukemia. On the
other hand, while previous studies have proposed a
recessive gain-of-function by MLL-PTD in suppressing
the expression of wild-type MLL in normal karyotype
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Figure 1. MLL amplification perturbs myeloid development in mouse models. Total cell counts in (A) bone marrow (2 femurs), (B) thymus and (C) spleen of the
control MLL(0), MLL(10-15), MLL(80-100) and MllPTD/WT mice. (D) Total colony numbers generated from bone marrow cells of MLL(n) and MllPTD/WT mice. Bone
marrow colonies were classified into burst forming unit-erythroid (BFU-E), colony forming unit-granulocyte (CFU-G), CFU-macrophage (CFU-M), CFU-granulo-
cyte/macrophage (CFU-GM), and CFU-granulocyte/erythroid/macrophage/megakaryocyte (CFU-GEMM). (E) Absolute number and (F) relative proportion of each
colony type from the bone marrow of indicated genotypes. (G) Total colony numbers formed from splenocytes of MLL(0) control, MLL(n) and MllPTD/WT mice. (H)
Absolute number and (I) relative proportion of each colony type from the spleen of indicated genotypes. (J) Percentages of myeloid cell populations (Total: Gr-
1+ or Mac-1+, Gr-1+Mac-1+, Gr-1+Mac-1- and Gr-1-Mac-1+) in spleens of MLL(0) control, MLL(n) and MllPTD/WT mice. (K) Representative flow cytometry plots showing
percentages of Gr-1+Mac-1+ cell population in spleens of MLL(0) control,  MLL(n) and MllPTD/WT mice. (L) Splenocytes (20x104 cells) from different mice were
seeded into methylcellulose for replating assays. Enumeration of colonies and replating of cells to the next round were performed after 6 days of culture. (M)
Flow cytometry analysis of the third round of replating MllPTD/WT splenic colonies. Red dots, unstained cells; blue dots, cells stained with indicated antibodies.
Results in panel A to C were obtained from 5 independent experiments, panel D to I were obtained from 6 independent experiments, whereas panel J and L






AML,5 both MllPTD/WT and MllPTD/- mice failed to develop
leukemia, thus questioning the role of MLL-PTD in acute
leukemogenesis and indicating a requirement of cooper-
ating mutation(s) for full malignant transformation.6,7
Intriguingly, MLL-PTD can be found to co-exist with
MLL(n) in AML patients,8,9 suggesting an alternative
pathological relationship between these 2 MLL aberra-
tions in myeloid leukemogenesis. 
To gain insights into the role of MLL(n) and MLL-PTD
in hematopoietic development, we generated an in vivo
mouse model of MLL amplification where the full-length
human MLL cDNA was expressed under the murine 
Scl-promoter/3'enhancer (Online Supplementary Figure
S1A), which has been successfully used to drive onco-
gene expression in hematopoietic stem and progenitor
haematologica 2017; 102:e301
LETTERS TO THE EDITOR
Figure 2. Potential cooperation between MLL amplification and MLL-PTD results in leukemic transformation in MLL(40-50)PTD/WT mice. (A) Survival curves of
MLL(40-50) (n=14), MllPTD/WT (n=12) and MLL(40-50)PTD/WT (n=12) mice. Three out of 12 MLL(40-50)PTD/WT mice developed AML but none of the control mice
showed any sign of disease (*P<0.05). (B) Representative images of spleens from MLL(0), MLL(40-50), MllPTD/WT and leukemic MLL(40-50)PTD/WT mice. All control
mice were age-matched to leukemic mice. Scale bar, 1 cm. Total cell counts in (C) bone marrow (2 femurs) and (D) spleens of MLL(0), MLL(80-100), MllPTD/WT
and leukemic MLL(40-50)PTD/WT mice. (E) Peripheral blood smears and cytospins of the cells prepared from the bone marrow, spleen and liver of MLL(0), MLL(40-
50), MllPTD/WT and MLL(40-50)PTD/WT mice are shown. Leukemic blasts are indicated by blue arrows. Cells were stained with May-Grunwald-Giemsa. Scale bars rep-
resent 30 mm. (F) Relative expression levels of Hoxa9 in MLL(n), MllPTD/WT, leukemic MLL(40-50)PTD/WT bone marrow and MLL-AF9 leukemic cells compared to E2A-
PBX leukemic cells by q-RT-PCR. (G) Relative expression levels of Hoxa9 in MLL(n), MllPTD/WT, leukemic MLL(40-50)PTD/WT splenocytes and MLL-AF9 leukemic cells
compared to E2A-PBX leukemic cells by q-RT-PCR. (H) Relative expression of HOXA9 in human MLL(n)-PTD bone marrow cells and in normal karyotype AML (NK-








cells (HSPCs) resulting in AML.10 Two different founders
with 10-15 and 40-50 copies of concatemeric transgenes
were selected for establishment of stable lines containing
10-15 (MLL(10-15)) or 80-100 copies (MLL(80-100)) of
MLL, respectively (Online Supplementary Methods and
Online Supplementary Figure S1B,C). Western blotting and
quantitative reverse transcription polymerase chain reac-
tion (RT-PCR) confirmed the transgene expression as
being, approximately, a 3-5- and 6-10-fold increase in the
bone marrow and spleen of MLL(10-15) and MLL(80-
100) mice, respectively (Online Supplementary Figure
S2A,B).  These findings are consistent with previously
reported Scl-enhancer’s property10 and in line with the
expression level of MLL in human MDS/AML patients
carrying 5-10 or more than 10 copies of MLL with,
approximately, a 1.5- and 9-fold increase, respectively.11 
To investigate the impacts of MLL amplification on
normal hematopoiesis, MLL(n) mice at three months old
were analyzed in parallel with MllPTD/WT mice and non-
transgenic control (MLL(0)). Although no significant dif-
ference in total cellularity was found in bone marrow and
thymus, a significant increase in splenic cells was
observed in MllPTD/WT mice (Figure 1A-C). In contrast, a
reduction in splenic cells was found in MLL(n) mice,
especially in MLL(80-100) mice (Figure 1C), suggestive of
a mild differentiation and/or proliferation defect.
Consistently, the splenocytes of MLL(10-15) and
MLL(80-100) mice displayed a trend towards a significant
increase in the percentage of Annexin-V+PI– apoptotic
cells compared to those of MLL(0) mice (Online
Supplementary Figure S2C), providing a potential explana-
tion for the lower cellularity observed in the spleen of
MLL(n) mice.  Functionally, MllPTD/WT bone marrows pro-
duced approximately 4 times more colonies than those
by MLL(n) and the control (Figure 1D,E). While the ratio
between each colony type remained constant in MllPTD/WT,
MLL(80-100) had a significant increase in the percentage
of colony forming units-granulocyte/monocyte (CFU-
GM) and a decrease in the percentage of colony forming
unit-granulocyte (CFU-G; Figure 1F), consistent with a
mild shift to immature myeloid. MLL(n) splenocytes
showed a slightly but significantly higher colony forming
ability (Figure 1G,H), where they consistently exhibited
an increase in immature colony forming units-granulo-
cyte/erythrocyte/macrophage/megakaryocyte (CFU-
GEMM) and burst forming units-erythroid (BFU-E; Figure
1I). The degrees of expansion were even more notable in
MLL(n) mice with a higher copy number of the MLL
transgene (Figure 1G-I), suggesting an aberrant selection
of proliferative myeloid clones. While there was no
apparent difference in the proportions of B cells and T
cells in these mice (Online Supplementary Figure S3A), an
expansion of the Gr-1+Mac-1+ cell population was found
in the MLL(80-100) spleen (Figure 1J,K). Consistently, a
transient enhanced replating ability was observed in
MLL(n) and MllPTD/WT splenocytes (Figure 1L). Compared
to non-transgenic controls, MLL(10-15) and MLL(80-100)
splenocytes, the latter in particular, were able to form a
substantial number of secondary colonies (Figure 1L).
MllPTD/WT splenocytes were able to generate compact
myeloid colonies even in the third round of replating
(Figure 1L,M). In contrast, there was no obvious differ-
ence in the replating ability of bone marrow cells (Online
Supplementary Figure S3B), consistent with the observed
phenotypes in these mice (Figure 1A-C). 
Apart from a significant decrease in the percentage of
common lymphoid progenitors (CLPs) in the bone mar-
row of MllPTD/WT mice, further investigation into the effect
of MLL(n) and PTD on early HSPC populations revealed
no significant difference in hematopoietic stem cells
(long-term (LT)-HSCs, short-term (ST)-HSCs), early
myeloid/lymphoid progenitor (multipotent progenitors
[MPPs], common myeloid progenitors [CMPs], granulo-
cyte-monocyte progenitors  [GMPs], megakaryocyte-ery-
throid progenitors [MEPs]), or lymphoid (B-[B220+], 
T-[CD4+CD8– and CD4–CD8+]) cell populations in their
bone marrows (Online Supplementary Figure S3C-E). RT-
qPCR confirmed the over-expression of MLL in c-kit+
HSPC bone marrow cells, albeit to a lesser extent than in
whole bone marrow cells in MLL(n) mice (Online
Supplementary Figure S3F,G), suggesting that mild over-
expression of MLL or MLL-PTD alone has a rather limit-
ed impact on HSPC compartments. Consistently, none of
the animals developed leukemia during two years of
observation (Online Supplementary Figure S3H), indicating
that additional events are required for overt leukemia as
observed in humans. 
On the other hand, the recurrent reports of AML pos-
sessing both MLL(n) and MLL-PTD8,9 raise the intriguing
possibility that these 2 different MLL aberrations may
collaborate in acute leukemogenesis.1 To address this
long outstanding question, we crossed MLL(80-100) with
MllPTD/WT mice to produce a novel double mutant MLL(40-
50)PTD/WT mouse (Online Supplementary Figure S1C and S4).
In contrast to MLL(40-50) and MllPTD/WT controls, which
did not develop any malignancy, 3 out of 12 MLL(40-
50)PTD/WT mice succumbed to AML with immature
myeloblasts and splenomegaly after 7 to 21 months
(P=0.0434) (Figure 2A-D). Examination of peripheral
blood revealed anemia and circulating myeloblasts
(Figure 2E), which also infiltrated the spleen and liver and
resulted in an alteration in their normal architecture
(Online Supplementary Figure S5 and Online Supplementary
Table S1). Flow cytometric analysis further confirmed
expansion of Gr-1+Mac-1+c-kitlow myeloblasts (Online
Supplementary Figure S6A), which was in contrast to a
drastic reduction of B220+ cells (Online Supplementary
Figure S6B). These results indicate that MLL amplification
and MLL-PTD cooperate to block normal myeloid differ-
entiation and to induce their aberrant expansion leading
to overt AML.
To gain further molecular insights underlying these
cooperating MLL aberrations, we assessed the transcrip-
tional and epigenetic status of Hoxa9, a key downstream
target for MLL leukemongenesis.12,13 By comparison with
MLL(40-50), MllPTD/WT controls and E2A-PBX mouse
leukemic cells, which expressed basal level of Hoxa9,
MLL(40-50)PTD/WT leukemic cells, in particular those from
the spleen, expressed  significant  levels of Hoxa9; almost
10-fold higher than MLL(40-50) and twice more than
MllPTD/WT; showing the possibility of functional coopera-
tion in MLL aberrations (Figure 2F-G).  In addition to
Hoxa9, a considerably higher level of Meis1,1 another tar-
get for MLL leukemongenesis, was also detected in
MLL(80-100) and MLL(40-50)PTD/WT bone marrow cells,
which provides an explanation for the transformation in
the double mutants (Online Supplementary Figure S7A). To
further confirm this finding in the relevant human dis-
ease, we also examined the expression and epigenetic
status of HOXA9 in primary human AML blasts carrying
both MLL(n) and MLL-PTD (Online Supplementary Figure
S7B). HOXA9 was significantly over-expressed in all 3
MLL(n)-PTD samples and MLL-AF6 leukemia as com-
pared to normal karyotype AML (Figure 2H). 
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At the epigenetic level, similar to MLL-AF9 mouse
leukemic cells, we observed an upregulation of the
H3K4me3 and H3K79me2 activation marks and a reduc-
tion of H3K9me2 repressive mark in MLL(40-50)PTD/WT
bone marrow cells, where higher levels of MLL expres-
sion were detected in comparison with non-transgenic
controls or Mll-PTD (Figure 3A,B). Interestingly, Kühn et
al. have observed profound enrichment of H3K79me2
marks at the highly expressed HOXA cluster locus in
MLL-PTD positive leukemia cell lines.14 They found that
DOT1L inhibition abrogated H3K79me2 and led to
downregulation of MLL targets in MLL-PTD leukemia
cell lines,14 suggesting that DOT1L is a potential thera-
peutic target for MLL-PTD leukemia. Consistent with the
mouse model, we also observed similar histone modifica-
tion patterns in human MLL(n)-PTD blasts (Figure 3C).
While MLL(n)-PTD samples exhibited an increased
H3K79me2 mark, it was significantly lower than that
seen in MLL fusion leukemia. Conversely, H3K4me3 was
invariably present at a high level in all MLL(n)-PTD sam-
ples (Figure 3C), which is in line with the detection of ele-
vated expression of wild-type MLL in primary AML
patients (Figure 3D), suggesting that H3K4me3 mediated
by the MLL/SET family may also play a critical role for
activation of downstream targets in these leukemias. To
further test this hypothesis, pharmacological inhibition of
MLL catalytic activity by a small molecule inhibitor
WDR-010315 significantly reduced cell viability (Figure
3E), induced cell differentiation (Figure 3F) and repressed
ribonucleic acid (RNA) expression of Meis1 (Figure 3G) of
haematologica 2017; 102:e303
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Figure 3. RNA expression and histone modifications of HOXA9 in MLL(40-50)PTD/WT mice and MLL(n)-PTD patients. (A) Fold change of H3K4me3, acetyl H3,
H3K79me2 and H3K9me2 histone marks within the Hoxa9 locus are shown. Results were obtained from 4 independent experiments. (B) Relative expression
levels of MLL in the bone marrow of MllPTD/WT, MLL(n), and pre-leukemic MLL(40-50)PTD/WT mice compared to age-matched wild-type MLL(0) mice (left panel),
pre-leukemic and leukemic MLL(40-50)PTD/WT mice compared to age-matched wild-type MLL(0) mice (right panel). Results were obtained from 5 mice with the
exception of MLL(40-50)PTD/WT where only 3 mice were available. (C) Fold change of H3K4me3, acetyl H3, H3K79me2 and H3K9me2 histone marks within the
HOXA9 locus using bone marrow cells from human MLL(n)-PTD, NK-AML, and MLL-AF6 samples. Results were obtained from 3 independent experiments. (D)
Relative expression levels of MLL in human primary samples with MLL(n)-PTDs, MLL fusions and PML-RARa compared to NK-AML. Expression of Gapdh was
used as an endogenous control to standardize the cDNAs. Results were obtained from 3 independent experiments. Bar graphs show mean+S.E.M. (*P<0.05,
**P<0.01 and ***P<0.001, paired t-test). (E) Relative cell viability (n=3), (F) cytospins and (G) RNA levels of Meis1 (n=2) of BM 2 and spleen 2 from MLL(40-
50)PTD/WT, E2A-PBX and MLL-AF9 mouse cells treated with 40 mM WDR5-0103 for 5 days. Red arrows indicate differentiated cells. Scale bars represent 6.25 mm.




MLL(40-50)PTD/WT transformed cells, supporting the fact
that the histone methyltransferase activity of MLL is cru-
cial for transcriptional activation and downstream leuke-
mogenesis.
In spite of their frequent association with poor prog-
nostic AML, the lack of appropriate leukemia models has
significantly hindered the progress in understanding the
function of MLL-PTD and MLL amplification in leukemo-
genesis.1,2 While the relatively long latency and partial
penetrance of AML in MLL(40-50)PTD/WT mice indicate the
requirement of additional events, such as genes co-ampli-
fied in the 11q23 amplicon8,9 for the development of full-
blown leukemia, the study herein provides the first
experimental evidence and novel insights into a coopera-
tive transformation mechanism mediated by MLL-PTD
and MLL amplification to induce leukemia in part by epi-
genetic deregulation of MLL downstream targets.
Intriguingly, both gain-of-function and loss-of-function
MLL mutations have been reported in acute leukemia,
indicating that the appropriate activity of MLL is required
for normal development, and its deregulation in either
direction can lead to leukemogenic transformation.1
Instead of being a passive player in MLL-PTD leukemia,
the study herein demonstrates the pathogenic functions
and potential therapeutic value of targeting MLL amplifi-
cation in acute leukemogenesis. 
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